Patents by Inventor Elena CUBERO JORDÀ

Elena CUBERO JORDÀ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl compounds and their use
    Patent number: 11739072
    Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: August 29, 2023
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Xavier Barril Alonso, Elena Cubero Jordà, Marc Revés Vilaplana, Richard Spurring Roberts
  • COMBINATION THERAPY FOR TREATING MPS1
    Publication number: 20230140216
    Abstract: The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3’, R4, R4’ and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with ?-L-iduronidase or an analog or variant thereof, e.g., laronidase.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 4, 2023
    Applicant: GAIN THERAPEUTICS SA
    Inventors: Ana Maria GARCÍA COLLAZO, Elena CUBERO JORDÀ, Xavier BARRIL ALONSO, Roberto MAJ, Natalia PEREZ CARMONA
  • HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE
    Publication number: 20230107499
    Abstract: The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R1a, R2a, R3a, A1, A2, A3, R1b, R2b, R3b, B1, and B2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and ?-synucleinopathies, such as Parkinson's disease.
    Type: Application
    Filed: November 25, 2020
    Publication date: April 6, 2023
    Applicant: GAIN THERAPEUTICS SA
    Inventors: Ana Maria GARCÍA COLLAZO, Elena CUBERO JORDÀ, Manolo BELLOTTO, Enrique FERNÁNDEZ IGLESIAS
  • ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE
    Publication number: 20230058312
    Abstract: The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, N pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and ?-synucleinopathies, such as Parkinson's disease.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 23, 2023
    Applicant: GAIN THERAPEUTICS SA
    Inventors: Ana Maria GARCÍA COLLAZO, Elena CUBERO JORDÀ, Xavier BARRIL ALONSO, Manolo BELLOTTO
  • Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
    Patent number: 11440898
    Abstract: The application is directed to compounds of formula (I):(I), and formula (IA):(IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: September 13, 2022
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Marc Martinell Pedemonte, Elena Cubero Jordà, Xavier Barril Alonso, Laura Pilar Rodriguez Pascau
  • HETEROARYL COMPOUNDS AND THEIR USE
    Publication number: 20220135535
    Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.
    Type: Application
    Filed: October 6, 2021
    Publication date: May 5, 2022
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Xavier Barril Alonso, Elena Cubero Jordà, Marc Revés Vilaplana, Richard Spurring Roberts
  • Heteroaryl compounds and their use
    Patent number: 11174242
    Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 16, 2021
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Xavier Barril Alonso, Elena Cubero Jordà, Marc Revés Vilaplana, Richard Spurring Roberts
  • ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE
    Publication number: 20200071294
    Abstract: The application is directed to compounds of formula (I):(I), and formula (IA):(IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B.
    Type: Application
    Filed: December 27, 2017
    Publication date: March 5, 2020
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Ana Maria GARCÍA COLLAZO, Marc MARTINELL PEDEMONTE, Elena CUBERO JORDÀ, Xavier BARRIL ALONSO, Laura Pilar RODRIGUEZ PASCAU
  • HETEROARYL COMPOUNDS AND THEIR USE
    Publication number: 20190337922
    Abstract: The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of a lysosomal storage disease, such as Gaucher's, and other diseases or disorders that are synucleinopathies.
    Type: Application
    Filed: December 28, 2017
    Publication date: November 7, 2019
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Ana Maria GARCÍA COLLAZO, Xavier BARRIL ALONSO, Elena CUBERO JORDÀ, Marc REVÉS VILAPLANA, Richard Spurring ROBERTS